The Board of Directors of the Company have approved the Audited Financial Results for the quarter and year ended March 31, 2026 at their meeting held on May 29, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Pharmaids Pharmaceuticals reported audited standalone revenue of Rs. 1,060.25 lakh for FY2026, up sharply from Rs. 234.09 lakh in FY2025, representing over 350% revenue growth. However, the company continues to incur significant losses with standalone net loss of Rs. 1,043.72 lakh (vs Rs. 727.92 lakh loss in FY2025). Consolidated revenue grew 43% to Rs. 2,788.24 lakh, with consolidated net loss improving to Rs. 1,157.19 lakh from Rs. 1,350.51 lakh. The Board also approved a Rs. 75 lakh corporate guarantee for subsidiary Adita Bio Sys Private Limited under ECLGS 5.0 scheme. Statutory auditors PPKG & Co issued an unmodified (clean) audit opinion with no going concern or qualified opinion flags. Cash position remains tight with standalone cash at Rs. 10.79 lakh.
Despite strong revenue growth, the company remains deeply loss-making with negative operating cash flows of Rs. 353 lakh standalone. The guarantee to subsidiary adds contingent liability exposure. While auditors gave clean opinion, persistent losses and thin cash reserves are concerning for shareholders.